Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (1-10 of 434) with videos related to

Pageof 44
Sort By:
Best Practice & Research. Clinical Haematology|March 25, 2021
Immune checkpoint inhibitors in acute myeloid leukemiaNaval Daver
Blood|March 6, 2020
A bispecific approach to improving CAR T cells in AMLNaval Daver
Oncology (Williston Park, N.Y.)|February 8, 2019
The Emerging Profile of Immunotherapy Approaches in the Treatment of AMLNaval Daver
The Lancet. Haematology|August 2, 2023
Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemiaMusa Yilmaz, Naval Daver
The Lancet. Oncology|August 1, 2017
FLT3 inhibition in acute myeloid leukaemiaNaval Daver, Hagop Kantarjian
Advances in Experimental Medicine and Biology|January 1, 2022
An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!Fadi Haddad, Naval Daver
The American Journal of Managed Care|August 23, 2018
Unmet clinical needs and economic burden of disease in the treatment landscape of acute myeloid leukemiaMegan Wiese, Naval Daver
South Asian Journal of Cancer|April 4, 2015
The changing face of acute myeloid leukemia therapeutics in the elderly populationNaval Daver, Jorge Cortes
Drugs|June 22, 2019
From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid LeukemiaMusa Yilmaz, Naval Daver
The Lancet. Oncology|February 19, 2017
Malignancy-associated haemophagocytic lymphohistiocytosis in adultsNaval Daver, Hagop Kantarjian
Pageof 44

Showing results (1-10 of 434) with videos related to

Sort By:
Pageof 44
Best Practice & Research. Clinical Haematology|March 25, 2021
Immune checkpoint inhibitors in acute myeloid leukemiaNaval Daver
Blood|March 6, 2020
A bispecific approach to improving CAR T cells in AMLNaval Daver
Oncology (Williston Park, N.Y.)|February 8, 2019
The Emerging Profile of Immunotherapy Approaches in the Treatment of AMLNaval Daver
The Lancet. Haematology|August 2, 2023
Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemiaMusa Yilmaz, Naval Daver
The Lancet. Oncology|August 1, 2017
FLT3 inhibition in acute myeloid leukaemiaNaval Daver, Hagop Kantarjian
Advances in Experimental Medicine and Biology|January 1, 2022
An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!Fadi Haddad, Naval Daver
The American Journal of Managed Care|August 23, 2018
Unmet clinical needs and economic burden of disease in the treatment landscape of acute myeloid leukemiaMegan Wiese, Naval Daver
South Asian Journal of Cancer|April 4, 2015
The changing face of acute myeloid leukemia therapeutics in the elderly populationNaval Daver, Jorge Cortes
Drugs|June 22, 2019
From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid LeukemiaMusa Yilmaz, Naval Daver
The Lancet. Oncology|February 19, 2017
Malignancy-associated haemophagocytic lymphohistiocytosis in adultsNaval Daver, Hagop Kantarjian
Pageof 44